相关实验视频
Updated: Jun 6, 2025

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
526
在患有心力衰竭的糖尿病患者中使用-葡萄糖共载体-2 抑制剂:最新情况
Nicia I Profili1, Roberto Castelli1, Antonio Gidaro2
1Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
概括
起初用于2型糖尿病的-葡萄糖共运输体-2抑制剂对心力衰竭患者显示出显著的益处. 这些药物可以改善心血管健康并治疗心力衰竭,无论糖尿病状况如何.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病和心力衰竭经常同时存在,特别是在老年患者中.
- 血糖水平升高会对心血管系统产生不利影响,恶化血糖控制.
- 血糖控制不良会加剧心力衰竭的开始和复发.
研究的目的:
- 审查-葡萄糖携运输体-2 抑制剂 (SGLT2 抑制剂) 在治疗心力衰竭方面的疗效.
- 探索超出血糖控制的SGLT2抑制剂对心血管的益处.
主要方法:
- 对SGLT2抑制剂的临床试验和研究的分析.
- 对SGLT2抑制剂在心力衰竭中作用的机制的检查.
主要成果:
- SGLT2 抑制剂通过糖尿降低血糖,降低心血管风险.
- 这些抑制剂具有利尿作用,有利于心力衰竭管理.
- 有证据表明,SGLT2抑制剂可以改善心力衰竭的治疗,无论血糖控制如何.
结论:
- SGLT2 抑制剂在治疗慢性和急性心力衰竭方面都表现出有效性.
- SGLT2 抑制剂对心血管的益处扩展到没有糖尿病的患者.
- SGLT2 抑制剂代表了心力衰竭管理的重大治疗进步.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343

